Results 291 to 300 of about 169,813 (342)

PDIA3 Inhibition Facilitates Sensitivity of IKE‐Induced Ferroptosis via STAT3/LCN2 Axis to Improve Glioblastoma Therapy

open access: yesAdvanced Science, EarlyView.
In this manuscript, protein disulfide isomerase A3 (PDIA3) is identified as a key factor mediating the susceptibility of ferroptosis in GBM. Inhibition of PDIA3 enhances IKE or cystine starvation‐induced ferroptosis in GBM cells by resulting in the accumulation of lipid peroxidation and a reduction in GSH level.
Jie Zhang   +19 more
wiley   +1 more source

CD169+ Macrophage‐Targeted Immunomodulator to Restore Phagocytic Function and Enhance Antigen Presentation for Lymphatic Metastasis Eradication

open access: yesAdvanced Science, EarlyView.
A CD169+ macrophage‐targeted immunomodulator (G‐LNP@S‐D) is developed to co‐deliver a SHP2 inhibitor and STING agonist, thereby restoring phagocytic function, enhancing antigen presentation by CD169+ macrophages, and promoting T cell priming to eradicate lymphatic metastasis.
Xiayun Chen   +9 more
wiley   +1 more source

A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β

open access: yesAdvanced Science, EarlyView.
This study demonstrates that the expression of A20, a ubiquitin‐editing enzyme, is positively correlated with oxaliplatin sensitivity in colorectal cancer (CRC). Mechanistically, A20 enhances oxaliplatin sensitivity by inhibiting NF‐κB nuclear translocation through monoubiquitination of IKK‐β.
Fan Luo   +12 more
wiley   +1 more source

AP2M1 Amplification Orchestrates Notch‐Mediated Chemoresistance in Hematopoietic Stem Cells of Acute Myeloid Leukemia Patients

open access: yesAdvanced Science, EarlyView.
The precise regulation of AP2M1 is essential for normal hematopoiesis. Overexpression of AP2M1 negatively affects the clinical outcomes of AML patients. Upregulation of AP2M1 enhances stemness and chemoresistance in HSPC cells of AML. AP2M1 modulates NOTCH1 expression, enhancing the Notch1 signaling pathway.
Hansong Lee   +28 more
wiley   +1 more source

IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial

open access: yesBlood Cancer Journal
Sheng-Li Xue   +32 more
doaj   +1 more source

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias

open access: yesAdvanced Science, EarlyView.
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei   +32 more
wiley   +1 more source

A pH‐Responsive Biomimetic Antioxidant Nanoplatform with Dual Renal Targeting for Synergistic Therapy of Acute Kidney Injury

open access: yesAdvanced Science, EarlyView.
A biomimetic nanoplatform (CeAst@MK) is engineered for precise therapy of acute kidney injury by integrating cerium‐based antioxidation, natural flavonoid astragalin, and macrophage membrane camouflage. Featuring kidney‐targeted and pH‐responsive release, CeAst@MK scavenges ROS, suppresses inflammation, and restores renal function via modulation of ...
Shichao Zhang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy